OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
Trial details
- Registry ID
- NCT04757610
- Drugs studied
- 0.5 mg ranibizumab, 2.0 mg OPT-302, Sham
TrialRedline tracks 2 clinical trials sponsored by Opthea Limited: 2 Phase 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)NCT04757610 | 0.5 mg ranibizumab, 2.0 mg OPT-302, Sham | Terminated | 2025-03-31Actual |
| OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)NCT04757636 | 2.0 aflibercept, 2.0 mg OPT-302, Sham | Terminated | 2025-03-31Actual |
Names as written in the registry records.